Connor Clark & Lunn Investment Management Ltd. Lowers Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Key Points

• Connor Clark & Lunn Investment Management Ltd. has reduced its position in Supernus Pharmaceuticals by 14.5%, owning 172,259 shares worth approximately $5.64 million after selling 29,310 shares in the 1st quarter.
• CEO Jack A. Khattar sold 140,000 shares at an average price of $42.02, representing an 11.96% decrease in his ownership, now holding over 1 million shares valued at approximately $43.29 million.
• Analysts recently upgraded Supernus Pharmaceuticals from a "hold" to a "buy" rating, with Cantor Fitzgerald raising the target price from $42.00 to $46.00.

Connor Clark & Lunn Investment Management Ltd. reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,259 shares of the specialty pharmaceutical company's stock after selling 29,310 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.31% of Supernus Pharmaceuticals worth $5,641,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of SUPN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Supernus Pharmaceuticals by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after purchasing an additional 1,083 shares during the period. Two Sigma Advisers LP boosted its holdings in Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after purchasing an additional 1,000 shares during the period. Principal Financial Group Inc. boosted its holdings in Supernus Pharmaceuticals by 3.2% in the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after purchasing an additional 9,590 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Supernus Pharmaceuticals by 6.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after purchasing an additional 3,495 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after purchasing an additional 6,867 shares during the period.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 140,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total value of $5,882,800.00. Following the sale, the chief executive officer directly owned 1,030,183 shares in the company, valued at $43,288,289.66. This trade represents a 11.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.80% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $41.24 on Wednesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $43.62. The stock has a market cap of $2.31 billion, a PE ratio of 35.86 and a beta of 0.74. The stock's fifty day moving average is $33.78 and its two-hundred day moving average is $33.47.

Wall Street Analysts Forecast Growth

SUPN has been the subject of a number of recent research reports. Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.